Abstract

The overall objectives of the Phase II effort are to develop additional antibodies against cyclic nucleotides (including cCMP) to compliment the antibodies generated during the fulfillment of prototype non-isotopic immunoassays for the measurement of cyclic nucleotides, and to complete the development of the assays in collaboration with BAbCO's Phase III partner (Boehringer Mannheim).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Small Business Innovation Research – Phase II (N44)
Project #
N44ES022004-000
Application #
2308743
Study Section
Project Start
1992-09-30
Project End
1994-09-29
Budget Start
1992-09-30
Budget End
1993-04-30
Support Year
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
Berkeley Antibody Company
Department
Type
DUNS #
City
Richmond
State
CA
Country
United States
Zip Code
94806